Influenza vaccine GSK2321138A

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline

Conditions

Influenza

Phase 2

Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine in Healthy Children

CompletedNCT00985790

GlaxoSmithKlineInfluenza

Start: 2009-10-08End: 2010-05-21Updated: 2018-09-21

Phase 3

Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children

CompletedNCT01196988

GlaxoSmithKlineInfluenza

Start: 2010-10-04End: 2011-06-15Updated: 2018-09-21

Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A)

CompletedNCT01204671

GlaxoSmithKlineInfluenza

Start: 2010-10-04End: 2011-06-06Updated: 2018-09-24

Related Papers

Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.

2014-12-0117 citations

Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.

2013-07-2483 citations

Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults.

2013-05-2051 citations

A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years.

2013-03-0782 citations